Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.
Jiangzhong Pharmaceutical announced its unaudited preliminary financial results for 2024, reporting a total operating revenue of RMB 443,545 ten thousand, a slight decrease of 2.59% compared to the previous year after adjustment. However, the company showed improvements in profitability with a 12.45% increase in operating profit and a 9.22% rise in net profit attributable to shareholders, indicating robust financial performance despite the revenue dip.
More about China Resources Pharmaceutical Group Ltd.
Jiangzhong Pharmaceutical Co., Ltd. is a Chinese company listed on the Shanghai Stock Exchange, with a significant ownership by China Resources Pharmaceutical Group Limited. The Group holds an effective interest of approximately 26.10%, classifying Jiangzhong Pharmaceutical as a subsidiary.
YTD Price Performance: -10.29%
Average Trading Volume: 3,217
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €3.95B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.
